We are committed to understanding and managing the environmental impacts of our products throughout their life cycles—from discovery through manufacturing, use and disposal.

RESOURCES
Public Policy Position Statement: PIE
Global Antimicrobial Resistance Action Plan
Public Policy Position Statement: Nanotechnology

We conduct environmental risk assessments on our products, from the development phase through product launch, to understand and manage product impacts from manufacturing and patient use. We assess products in a manner consistent with the most stringent applicable global regulations, including the regulatory review processes of the U.S. Food and Drug Administration and the European Medicines Agency. Product environmental safety profiles are reassessed during periodic renewals of product filings, and risk-mitigation actions are implemented when needed.

We carefully monitor scientific research on the issue of pharmaceuticals in the environment, including studies that evaluate the potential effects pharmaceutical products may have on the aquatic environment and human health.

Pharmaceutical compounds have been found to enter the environment primarily through the use of medicines by humans and animals, and the subsequent excretion into wastewater treatment systems, water bodies or soil. Other potential environmental routes include manufacturing wastewater discharges and waste disposal.

We use the information from our risk assessments to establish or update our internal, compound-specific Environmental Quality Criteria (EQCs), which are used to confirm that wastewaters discharged from our facilities do not contain residual products that present a risk to human health or the environment. Our manufacturing facilities are required to use these EQCs, along with industry-accepted risk-assessment methods, to establish procedures for managing and controlling active pharmaceutical ingredients (APIs) in their wastewater. We also provide EQC information to suppliers that manufacture pharmaceutical compounds for us. Our production facilities have, or are currently being provided with, API-treatment technology to ensure that our wastewater meets these EQCs. Our facilities are also required to incinerate any product...
We carefully monitor scientific research on the issue of pharmaceuticals in the environment (PIE), including studies that evaluate the potential effects pharmaceutical products may have on the aquatic environment and human health. We support the use of science-based environmental risk assessments, and we will continue to collaborate with regulatory, academic, health care and research organizations to identify additional needs for data on pharmaceuticals in the environment.

**STAKEHOLDER ENGAGEMENT AND ADVOCACY**

We participate in efforts to address PIE with various organizations, including the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

The EFPIA, Medicines for Europe, and the Association of the European Self-Medication Industry (AESGP) have worked together to develop the Eco-Pharmacostewardship (EPS) initiative. The EPS initiative considers the environmental impacts of a medicine throughout its entire life cycle and addresses the roles and responsibilities of all parties in managing those impacts, including public services, the pharmaceutical industry, environmental experts, doctors, pharmacists and patients. Our PIE Public Policy statement contains additional details on this initiative and covers how we address environmental risks in our drug filings, within our manufacturing plants, and with our suppliers and patients.

The IFPMA is spearheading the battle against antimicrobial resistance (AMR) for industry. Our company is helping to lead these industry efforts to minimize AMR risk from manufacturing while following a One Health approach to antimicrobial stewardship. As a member of the AMR Industry Alliance and signatory to the Industry Roadmap for Progress on Combating Antimicrobial Resistance, we are working to deliver on our commitments to reduce environmental impacts from the production of antibiotics. We are currently reviewing the operations of our third-party suppliers to assess good practice in controlling releases of antibiotics into the environment. We are also working with other AMR Industry Roadmap signatories and key stakeholders, including independent technical experts, to establish a common framework for managing antibiotic discharges, to develop a mechanism for transparently demonstrating that our supply chains meet the standards in this framework, and to establish science-driven, risk-based targets for discharge concentrations.